SIRTeX Medical | SIR-Spheres Y90 Resin Microspheres | Which Medical Device

Description

From SIRTeX Medical

Y90 resin microspheres                                                                                       

Important: The information contained within these pages, including evidence is only relevant to SirTex SirSpheres Y90 resin microspheres and should not be used in support of any other SIRT products.   

UK based clinician information here

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy or SIRT (also known as radioembolisation), a proven technology for inoperable liver tumours that delivers substantial, targeted doses of radiation directly to the cancer.

SIR-Spheres Y90 resin microspheres consist of biocompatible microspheres containing yttrium-90 with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy beta-emitting isotope with no primary gamma emission.

In a minimally invasive treatment, millions of SIR-Spheres Y-90 resin microspheres are infused via a catheter into the liver where they selectively target liver tumours with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing the adjacent healthy liver tissue.

Manufactured by Sirtex Medical Limited, SIR-Spheres Y-90 resin microspheres are approved in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, Switzerland, Turkey and several other countries in Asia such as India, Korea, Singapore, and Hong Kong for the treatment of liver tumours that are unable to be removed through surgery.

SIR-Spheres Y-90 resin microspheres also have a full Pre-Market Approval (PMA) from the US FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

Additionally, SIR-Spheres microspheres are supplied in countries such as Israel, Malaysia, New Zealand, Taiwan and Thailand.

Available at more than 700 treatment centres, over 45,000 doses of SIR-Spheres microspheres have been supplied worldwide.

Treatment Goals:
Increase the time to progression
Extend overall survival
Potentially downsize or downstage tumours for liver resection, ablation, or transplantation
Provide palliation of symptoms

SIRT can be combined with modern chemotherapy or administered as a monotherapy, either during a chemotherapy holiday, in a salvage setting or as an alternative to local chemotherapy.

Radiotherapy, together with chemotherapy and surgery, is a major pillar in the treatment of cancer. However, the utility of external beam radiation in the management of liver tumours is limited by the sensitivity of the uninvolved liver parenchyma to radiation.

Selective Internal Radiation Therapy with SIR-Spheres Y90 resin microspheres offers patients an opportunity to access radiotherapy for inoperable primary and secondary liver tumours whilst sparing normal liver parenchyma.

See the evidence tab for further clinical trial information here

Important: The information contained within these pages, including evidence is only relevant to Sirtex Sir-Spheres Y90 resin microspheres and should not be used in support of any other SIRT products.

 Publication on the use of SIR-Spheres Y90 resin microspheres          SIR-Spheres Y90 resin microspheres product site

 SIRT UK Network                                                Sir-Spheres product leaflet